|
WO2012104843A1
(en)
|
2011-02-06 |
2012-08-09 |
Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science |
Affinity maturated t cell receptors and use thereof
|
|
JP6712261B2
(ja)
*
|
2014-08-04 |
2020-06-24 |
フレッド ハッチンソン キャンサー リサーチ センター |
Wt−1に特異的なt細胞免疫治療
|
|
GB201417803D0
(en)
|
2014-10-08 |
2014-11-19 |
Adaptimmune Ltd |
T cell receptors
|
|
EP3067366A1
(en)
|
2015-03-13 |
2016-09-14 |
Max-Delbrück-Centrum Für Molekulare Medizin |
Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
|
|
US12364757B2
(en)
*
|
2015-10-01 |
2025-07-22 |
Ospedale San Raffaele S.R.L |
TCR and uses thereof
|
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
|
GB201520544D0
(en)
*
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
EP3219800A1
(en)
|
2016-03-15 |
2017-09-20 |
Max-Delbrück-Centrum Für Molekulare Medizin |
A transposon-based transfection system for primary cells
|
|
CN106749620B
(zh)
*
|
2016-03-29 |
2020-09-25 |
广东香雪精准医疗技术有限公司 |
识别mage-a1抗原短肽的t细胞受体
|
|
DK3440105T3
(da)
*
|
2016-04-08 |
2022-06-13 |
Immunocore Ltd |
T-cellereceptorer
|
|
CN106084042B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗MAGEA1的全分子IgG抗体及其应用
|
|
EP3515935A4
(en)
*
|
2016-09-23 |
2019-09-04 |
Lion TCR Pte. Ltd. |
HBV-Antigen specific binding molecules and fragments thereof
|
|
DE102016123847B3
(de)
*
|
2016-12-08 |
2018-04-05 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
MY192819A
(en)
*
|
2016-12-08 |
2022-09-12 |
Immatics Biotechnologies Gmbh |
Novel t cell receptors and immune therapy using the same
|
|
CN108250289B
(zh)
*
|
2016-12-28 |
2021-10-08 |
香雪生命科学技术(广东)有限公司 |
源自于mage b6的肿瘤抗原短肽
|
|
BR112019018863A8
(pt)
*
|
2017-03-15 |
2023-05-02 |
Hutchinson Fred Cancer Res |
Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
|
|
CN108929378B
(zh)
*
|
2017-05-22 |
2021-04-23 |
香雪生命科学技术(广东)有限公司 |
一种识别prame抗原的t细胞受体及编码该受体的核酸
|
|
WO2019046818A1
(en)
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
|
|
GB2596461B
(en)
*
|
2019-02-20 |
2023-09-27 |
Fred Hutchinson Cancer Center |
Binding proteins specific for RAS neoantigens and uses thereof
|
|
CA3131138A1
(en)
|
2019-03-06 |
2020-09-10 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
TWI850360B
(zh)
|
2019-04-04 |
2024-08-01 |
德商梅迪基因免疫治療公司 |
黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
|
|
PE20220231A1
(es)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso
|
|
EP3997116A1
(en)
*
|
2019-07-09 |
2022-05-18 |
Medigene Immunotherapies GmbH |
Magea10 specific t cell receptors and their use
|
|
GB201915282D0
(en)
*
|
2019-10-22 |
2019-12-04 |
Immunocore Ltd |
Specific binding molecules
|
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
|
CN113684258B
(zh)
*
|
2020-05-18 |
2024-08-20 |
上海赛比曼生物科技有限公司 |
用于检测鼠源tcr转基因拷贝数的试剂盒及方法
|
|
JP7781085B2
(ja)
*
|
2020-06-25 |
2025-12-05 |
ザ・メソジスト・ホスピタル |
抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法
|
|
IL276599A
(en)
*
|
2020-08-09 |
2022-03-01 |
Yeda Res & Dev |
T cell receptor unique to mage-a1 and its uses
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CN112279908B
(zh)
*
|
2020-10-23 |
2024-03-19 |
魏放 |
识别ebv抗原短肽的t细胞受体及其应用
|
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2023083864A1
(en)
|
2021-11-09 |
2023-05-19 |
T-Knife Gmbh |
Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CN114539386B
(zh)
*
|
2022-04-27 |
2022-07-26 |
恒瑞源正(广州)生物科技有限公司 |
Mage-a1特异性t细胞受体及其用途
|
|
CA3260083A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences Inc |
CD73 COMPOUNDS
|
|
CN120476137A
(zh)
|
2022-08-18 |
2025-08-12 |
英美偌科有限公司 |
对mage a4具有特异性的t细胞受体融合蛋白
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025027087A1
(en)
|
2023-07-31 |
2025-02-06 |
T-Knife Gmbh |
A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025027088A1
(en)
|
2023-07-31 |
2025-02-06 |
T-Knife Gmbh |
An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025045752A1
(en)
|
2023-08-25 |
2025-03-06 |
T-Knife Gmbh |
Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096983A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Board Of Regents, The University Of Texas System |
Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025146286A1
(en)
|
2024-01-04 |
2025-07-10 |
Immunoscape Pte. Ltd. |
Human t cell receptors and uses thereof
|
|
WO2025190565A1
(en)
|
2024-03-13 |
2025-09-18 |
T-Knife Gmbh |
A chimeric programmed cell death protein 1 receptor
|
|
WO2025191067A1
(en)
|
2024-03-13 |
2025-09-18 |
T-Knife Gmbh |
A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with ig and itim domains (tigit) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|